HSD11B1 exhibits oncogenic potential in primary imatinib-naïve gastrointestinal stromal tumors driven by HSD11B1 copy-number gain or missense mutations [23]. This evidence concerns the gene HSD11B1 and gastrointestinal stromal tumor.